Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound and composition for use in treatment of premenstrual syndrome and/or premenstrual dysphoric disorder

A technology for premenstrual syndrome and composition, applied in the direction of drug combination, anhydride/acid/halide active ingredients, drug delivery, etc., can solve the problem of poor effect, little use, no drug treatment and alternative treatment without side effects, etc. question

Pending Publication Date: 2021-12-24
SYNAPHARM IND SYNTHESIS
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Unfortunately, at present it appears that the main drug treatments have many side effects and the alternative treatments are relatively less effective and therefore not used much
[0012] Therefore, until today, there is no convincing drug treatment and alternative treatment without side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] The invention also relates to a composition for the treatment of premenstrual syndrome and / or premenstrual dysphoric disorder.

[0030] Advantageously, in the composition according to the invention, said magnesium N-acetyl-taurate is magnesium N-acetyl-taurate dihydrate comprising two intrinsic water molecules.

[0031] In the context of the present invention, the term "two intrinsic water molecules" means that these two water molecules are intrinsic to N-acetyl-magnesium taurate dihydrate, i.e. they are Hydrates are components other than bound water that can be absorbed or adsorbed by the compound.

[0032] Magnesium N-acetyl-taurate dihydrate (C 8 h 20 MgN 2 o 10 S 2 ) is the magnesium carrier and the magnesium analog of taurine, and its molecular weight is 392.677g / mol, and two water molecules (H 2 O) is intrinsic to the magnesium N-acetyl-taurate dihydrate molecule.

[0033] Specifically, magnesium N-acetyl-taurate dihydrate is commercially available from Synap...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a compound and a composition for use in the treatment of premenstrual syndrome and / or premenstrual dysphoric disorder.

Description

technical field [0001] The present invention relates to compounds and compositions for the treatment of premenstrual syndrome and / or premenstrual dysphoric disorder. Background technique [0002] Premenstrual syndrome (or PMS) is a group of conditions that occur before or during menstruation. It is characterized by symptoms such as swollen breasts, headaches, heaviness or weight gain in the legs, skin rashes or herpes, and behavioral or mood disturbances, including nervousness, anxiety, aggression, moodiness, and depression. Premenstrual dysphoric disorder (PMDD) is considered the most severe form of PMS. [0003] A literature review (Zaafrane et al., Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 36, 2007, 642-652) defines PMS as a collection of physical, emotional, and behavioral symptoms that appear before menstruation and disappear after menstruation ends. This review notes that this symptom cluster affects approximately 75% of women of reproductive...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/06A61K31/185A61P25/00A61P5/24A61K9/00
CPCA61K31/185A61K33/06A61P25/00A61P5/24A61K47/12A61K2300/00
Inventor 菲利普·丹希尔帕斯卡莱·阿扎姆
Owner SYNAPHARM IND SYNTHESIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com